Evidence map›Paper›PMID 26309621›Full record

ArticleInternational journal of clinical and experimental medicine2015

Relationship between ADH2 Arg47His variation and hepatocellular carcinoma susceptibility: a meta analysis.

Shuzhen Liu, Yongchun Cui, Baohong Yang, Ping Chai, Zheng Su, Qianqian Zhang, Dejie Zheng, Rui Li, Guohua Yu

Abstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuzhen LiuClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
Yongchun CuiDepartment of Drug Clinical Trial Institution of Shandong Cancer Hospital & Institute Jinan, Shandong, China.
Baohong YangClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
Ping ChaiClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
Zheng SuClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
Qianqian ZhangClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
Dejie ZhengClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
Rui LiClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
Guohua YuClinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo further investigate the relationship between ADH2 Arg47His variation and hepatocellular carcinoma (HCC) susceptibility through a meta-analysis.

methodsThe related articles were searched in PubMed, Embase and CNKI databases. And finally 518 cases and 607 controls were included in our meta-analysis Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the relationship between ADH2 Arg47His variation and HCC risk. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity.

resultsQuantitative synthesis demonstrated that no significant association was found between ADH2 Arg47His variation and HCC susceptibility (His/His vs. Arg/Arg: OR=0.99, 95% CI=0.79-1.25; His/His + Arg/His vs. Arg/Arg: OR=1.01, 95% CI=0.86-1.20; His/His vs. Arg/Arg + Arg/His: OR=0.90, 95% CI=0.74-1.11; His vs. Arg: OR=0.98, 95% CI=0.86-1.11; Arg/His vs. Arg/Arg: OR=1.05, 95% CI=0.82-1.34).

conclusionOur analysis showed that ADH2 Arg47His vvariation may not be associated with HCC susceptibility.

Indexed as

ADH2hepatocellular carcinomavariation

Identifiers

PMID26309621
PMCPMC4538084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.